Running all the way to the living room, Lin Yu didn't think much about it, he directly picked up his mobile phone and checked the detailed incident of Guan Xiaoboy's terminal cancer on Weibo.

Soon, Lin Yu understood all the ins and outs of the whole thing.

It's just that when Lin Yu learned that this little boy named Xiaoyi had advanced neuroblastoma cancer, he couldn't help frowning.

Because according to what he learned. In this 18-year parallel world, China has not yet had any immunotherapy for cancer in terms of solid tumors.

It is important to know that cancer immunotherapy is a new type of treatment that has emerged after surgery, chemotherapy, radiotherapy, and targeted therapy, known as cancer therapy, which uses the power of the patient's own immune system to fight cancer.

Not to mention Huaxia, even the top medical companies in the United States are still conducting various explorations and preliminary experiments on cancer immunotherapy.

Therefore, now hospitals are using traditional treatment methods to treat cancer.

But these traditional treatments are basically useless for Xiaoyi, who is now in the advanced stage of cancer, except to prolong her life cycle a little.

Although the CAR&ash;T cell immunotherapy obtained by Lin Yu in the system can act on both solid tumors and non-solid tumors, it also has limitations, and it only targets cancers in hematological tumors.

In other words, the therapeutic effect of Bai Ze inhibitors is only for all non-solid tumors in hematological tumors.

CAR&ash;T cell immunotherapy, on the other hand, is effective for all solid tumors and non-solid tumors in hematological tumors, and the effect is very perverted.

It is important to know that there are hundreds of cancers in hematological cancers, and generally speaking, each type of cancer corresponds to a unique targeted drug.

CAR&ash;T cell immunotherapy, which can be systematically rewarded, can be effective against all of these hundreds of cancers, so you can imagine how powerful its drug effect is.

However, even such a powerful CAR&ash;T cell immunotherapy has no solution for neuroblastoma.

Because it does not belong to the category of hematological tumors, but belongs to neuroendocrine tumors, CAR&ash;T cells have nothing to do with it.

Therefore, if you want to treat Xiaoyi's neuroblastoma, you can only reinvent a new cancer immunotherapy that specifically targets neuroendocrine tumors.

Thinking of this, Lin Yu couldn't help but breathe a sigh of relief, and immediately, a touch of firmness passed through his eyes.

Although he did not have the technology to treat neuroma from the system, he could use the god-level skill of superbrain to conduct research and development of neuroma immunotherapy using CAR&ash;T cell immunotherapy as an example.

Although he didn't know if he could find a targeted drug for neuroma in a short period of time and make it out of his own superbrain.

However, this time he just wanted to give it a try with all his might, and he would give it a try without any regrets!

After making up his mind, Lin Yu, who knew that the time was pressing, quickly began to act, and he immediately called Ouyang Lei, the CEO of Baiji Company, and asked him to prepare the relevant equipment, and bring a professional medical team for neuroma to wait for him in the immuno-oncology R&D center.

After speaking, Lin Yu quickly put on his clothes, pants and shoes, and after briefly talking to Su Muyun, under the latter's gentle and considerate gaze, he went downstairs to drive and drove towards Baiji Company at a high speed.

As for the comments left by many netizens on Weibo on his message board, Lin Yu didn't have time to reply.

Just as Su Muyun was standing at the window of his house, watching Lin Yu drive away, Su Muxin also happened to come out of the room.

Sister, what are you looking at?

As she spoke, Su Muxin walked over curiously, stood beside her, and put her little head out of the window.

After looking around for a while and didn't find anything special, Su Muxin couldn't help but pout, then retracted her little head, looked at Su Muyun on the side, and said pitifully: Sister, I'm hungry, why don't you go and urge your brother-in-law to cook, it's already halfway.

Su Muyun glanced at her lightly and said, Your brother-in-law just went out for a while, and it is estimated that he will come back tomorrow, you

I'm afraid it's impossible to get him to make dinner.

Hearing the news, Su Muxin was stunned for a moment, then came back to her senses and looked at her, and smiled: Since my brother-in-law is busy, when will you cook dinner, sister?

If you don't do it, you can order takeout, and by the way, help me order one.

Seeing Lin Yu drive completely out of his sight, Su Muyun turned around and walked towards the live broadcast bedroom without looking back.

Su Muxin: ???

Good guy, if the uncle doesn't come back, he won't even cook dinner.

You don't take me seriously at all.

It's really a sister!

After Su Muxin sighed helplessly, she finally made a bitter face, took out her mobile phone and began to order takeout, forced to accept this sad reality.

Meanwhile.

Half an hour later, Lin Yu stopped in the courtyard of Baiji Company's immuno-oncology R&D center.

After seeing him get out of the car, Ouyang Lei, who had been waiting for a long time, and Eric, the person in charge of the Immuno-Oncology R&D Center, also hurriedly greeted him.

Chairman, the team of neuroma professionals you want is already waiting for you in the GMP laboratory.

Ouyang Lei said as he introduced to Lin Yu: By the way, this is the person in charge of the Immuno-Oncology R&D Center, Eric, we met at dinner before, if you have any needs next, you can talk to him.

Well, hello, Eric, I'll trouble you later.

Lin Yu nodded, and then looked at the middle-aged foreigner with blond hair next to him with a smile.

It is simply our honor for the chairman to come to our immuno-oncology R&D center.

Eric just smiled modestly, and then looked at Lin Yu with fiery eyes: Forgive me for asking, I wonder if the chairman is going to develop immunotherapy for neuroma today?

Since Xiao Yi's matter on the Internet has become known all over the Internet, many people have been paying attention to it, even him.

Listening to Eric's words without any translation, Lin Yu glanced at him in surprise, then shook his head, and said: I don't have a specific idea yet, and I still need to verify my ideas one by one, so I don't know if it can be successfully developed.

Regarding the uncertainty in Lin Yu's words, Ouyang Lei patted Eric on the shoulder with a smile on his face, and said meaningfully: The chairman comes to verify the idea every time, but the result is successful every time, so I understand it.

Hearing this, Eric also showed a smile of sudden realization on his face.

It turns out that the chairman doesn't really know, but he is humble.

With such a rare noble quality at such a young age, he is indeed a dragon among people.

Thinking of this, Eric couldn't help but look at Lin Yu's eyes full of admiration.

Lin Yu:

Looking at the smiles of the two people in front of him that I understand, Lin Yu was also a little speechless for a while.

Why is it that every time he tells the truth, others don't believe him?

Moreover, I really don't know this time.

Sighing helplessly, Lin Yu didn't bother to talk to them, and walked directly towards the R&D center.

Seeing this, Ouyang Lei and Eric also followed with smiles on their faces.

Along the way, Lin Yu was a little unconfident about the firm smiles that the two of them had developed for neuroma immunotherapy.

Soon, the three of them came to the outside of the GMP laboratory.

Because of the non-professionals, Ouyang Lei didn't go in, only Lin Yu and Eric put on white masks and changed into white overalls to go in.

However, Lin Yu had already told Ouyang Lei in advance before he went in, saying that the research and development time this time might be long, and if he couldn't hold on, he could go back early.

In this regard, Ouyang Lei just waved his hand indifferently.

In his heart, Lin Yu's research time was only one night at most, how could he not be able to hold on.

When Lin Yu walked into the GMP laboratory, a professional team of thirty people was already waiting for him there.

Samples and tools for neuroblastoma and other related experiments have also been prepared.

Seeing this, Lin Yu didn't have any

Nonsense, directly and without hesitation, turn on the superbrain skill.

With the opening of Superbrain, Lin Yu's knowledge about tumor immunotherapy began to be based on CAR&ash;T cell immunotherapy, and countless new ideas and ideas continued to burst out.

While deducing the feasibility of the countless ideas in his mind, Lin Yu began to command in an orderly manner.

From now on, you form your own team, a group of people, to activate the donor's peripheral blood mononuclear cells with a high concentration of IL-2.

In the second group, lymphocytes were isolated from resected tumor tissue or cancerous thoracoascs fluid and activated and expanded by IL-2 induction in vitro. br>

In the three groups, DC cells were mixed with CIK cells to observe whether they could regulate each other, so as to increase cytokine release and enhance cytotoxicity.

In the four groups, gene editing technology was used to integrate a gene expressing interleukin factor 12 (L12) and let interleukin 12 be expressed locally at the target location.

As instructions came out of Lin Yu's mouth, these thirty professional teams also quickly operated and devoted themselves to research.

Even Eric, who was watching the play from the sidelines, was no exception and hurriedly joined their busy team.

After Lin Yu issued the order, he also devoted himself to the core technology research and development, constantly looking for antibodies to neuroblastoma.

Generally speaking, cancers of solid tumors can be said to be several times more powerful than cancers of non-solid tumors.

This is because solid tumors are able to form a microenvironment in patients with infiltrative regulatory T cells, tumor-associated macrophages, high PD-1 expression, and inhibitory cytokines.

They protect the tumor very tightly, like a heavily armed fortress, and targeted drugs cannot act on it at all, so the treatment effect is very weak.

Non-solid tumors are relatively simple, because they don't have a fortress, so as long as you find a specialized antibody, you can directly target them.

After four hours, all the ideas in the six groups failed, except for the fourth.

Even Lin Yu did not find a specific antibody to neuroblastoma.

However, they are not without gains, because they know that the fourth group of integrated expression of the interleukin-12 gene can improve the microenvironment for immunotherapy.

In other words, this interleukin-12 gene can summon nearby NK cells to activate, and awaken the function of infiltrating T cells, assisting CAR-T cells to kill the target negative and positive cells of solid tumors.

This is equivalent to directly penetrating the defensive fortress of solid tumors.

But unfortunately, this is only to break through the fortress, and it cannot eliminate the neuroblastoma inside.

Because they lack antibodies specifically against it.

For this achievement, except for Lin Yu, everyone else was a little excited.

Because in such a short period of time, they have broken through a technical problem of tumor immunity.

This is great news for them.

Soon, after a short period of disappointment, Lin Yu breathed a sigh of relief, adjusted his mentality, and constantly reflected on the series of orders that had just been issued, looking for what went wrong.

Soon, he found out why.

That is, he seems to have reversed his priorities, because he subconsciously thinks about problems in a way that focuses on CAR&ash;T cell immunotherapy, supplemented by neuroma knowledge points.

Since it is a cancer of neuroma, how can he use the method of hematological tumors.

Thinking of this, Lin Yu's eyes lit up instantly, and he began to learn the lessons of the failure just now, focusing on the knowledge points of neuroma, and constantly began to deduce its derivative ideas and ideas.

Soon, as countless thoughts erupted, Lin Yu continued to direct everyone to start a new study.

What made Lin Yu feel excited was that this time he found a large number of antigens &ash;&ash;GD2 present on the surface of neuroblastoma in the outer membrane of it!

This means that his idea is not wrong, and he can directly make antibodies against the target of GD2.

However, the objective response rate of this antibody

(ORR) only reached 45%

In addition to this, there was good news from the six groups.

The fourth group found that GD2 targeting can be combined with CAR&ash;T cell immunotherapy.

This not only improves the ability to recruit T cells, but also reduces the risk of non-specific T cell involvement and reduces the occurrence of side effects.

This is undoubtedly the second way out that can be used as an antibody to neuroblastoma.

Three hours later, Lin Yu successfully bound the T cells to the antibody using the GD2 and CART cell binding method found in the fourth group in BiClone format!

What's more, the objective response rate (ORR) of this antibody is a staggering 78%!

As of 6 a.m. the next morning, they had found a total of two antibodies against neuroblastoma!

For this unexpected result, Lin Yu finally showed a satisfied smile.

Immediately, after six hours of struggle in the morning, Lin Yu combined the two antibodies, took their essence, and removed their dross.

Eventually, he found a brand new antibody that was still predominantly CAR&ash;T cell immunotherapy, but against neuroblastoma!

And this new antibody has a terrifying remission rate of 95%!

After the news came out, all the researchers in the whole laboratory who had been working hard for a day and a night were red-eyed, hugging each other excitedly, cheering and jumping, very excited.

And this move immediately woke up Ouyang Lei, who was dozing off outside the door.

After seeing this scene, he also had a smile on his face that I knew.